Eating and Weight Disorders (Apr 2024)

Association of serotonin receptor gene polymorphisms with anorexia nervosa: a systematic review and meta-analysis

  • Arturo Bevilacqua,
  • Francesca Santini,
  • Daniela La Porta,
  • Silvia Cimino

DOI
https://doi.org/10.1007/s40519-024-01659-3
Journal volume & issue
Vol. 29, no. 1
pp. 1 – 16

Abstract

Read online

Abstract Purpose Several studies have investigated the association between anorexia nervosa and polymorphisms of genes regulating serotonin neurotransmission, with a focus on the rs6311 polymorphism of 5-HTR2A. However, inconsistent results of these studies and conflicting conclusions of existing meta-analyses complicate the understanding of a possible association. We have updated these results and evaluated the involvement of other serotonin receptor gene polymorphisms in anorexia nervosa. Methods Adhering to PRISMA guidelines, we have searched studies on anorexia nervosa and serotonin-regulating genes published from 1997 to 2022, selected those concerning receptor genes and meta-analyzed the results from twenty candidate gene studies on the 5-HTR2A rs6311 polymorphism and the 5-HTR2C rs6318 polymorphism. Results Present analyses reveal an association for the 5-HTR2A rs6311 polymorphism, with G and A alleles, across eighteen studies (2049 patients, 2877 controls; A vs. G allele, Odds Ratio = 1.24; 95% Confidence Interval = 1.06–1.47; p = 0.009). However, after geographic subgrouping, an association emerged only in a Southern European area, involving five studies (722 patients, 773 controls; A vs. G allele, Odds Ratio = 1.82; 95% Confidence Interval = 1.41–2.37; p < 0.00001). No association was observed for the 5-HTR2C rs6318 polymorphism across three studies. Conclusions To date, the involvement in the pathophysiology of anorexia nervosa of the 5-HTR2A rs6311 polymorphism appears limited to a specific genetic and/or environmental context, while that of the 5-HTR2C rs6318 polymorphism seems excluded. Genome-wide association studies and epigenetic studies will likely offer deeper insights of genetic and environmental factors possibly contributing to the disorder. Level of evidence III Evidence obtained from well-designed cohort or case–control analytic studies. Clinical trial registration PROSPERO registration number: CRD42021246122.

Keywords